the buyer says he is “relieved but aware of the immense task that remains to be accomplished”

On Monday, the Versailles Economic Court validated the takeover offer of the artificial heart manufacturer from Pierre Bastid, chairman of the board of directors.

Pierre Bastid, the buyer of Carmat, a French manufacturer of artificial hearts, said on Tuesday December 2 on franceinfo, “relieved but aware of the immense task that remains to be accomplished” the day after the decision of the Versailles Economic Court which validated its takeover offer. The company, which manufactures artificial hearts for patients awaiting heart transplants, was placed in receivership last July. Some 122 patients have already been transplanted with this artificial heart. Pierre Bastid also emphasizes that “30% of staff” will be laid off, so he will keep 88 of the 127 employees.

“My offer consists, not of reducing our ambitions, but of spreading them out over time”specifies Pierre Bastid, historic shareholder of Carmat. One of the objectives for Carmat is to be able to manufacture a definitive prosthesis. In 2026, “we are launching clinical studies to obtain this approval in France and it will probably take two to three years to obtain the qualification”he explains. Preliminary results of clinical studies already carried out “in a so-called effective framework (…) make us extremely confident”, underlines the one who is chairman of the board of directors of Carmat.

Its takeover offer also provides for the continuation of clinical studies carried out in the United States for “obtain certification” of the Carmat temporary prosthesis. And finally, the last axis is “seeking reimbursement for the prosthesis from Social Security and health organizations in France”specifies Pierre Bastid.

The buyer of Carmat plans to make a profit “probably in the second half of 2030, maybe 2031”. Pierre Bastid finally specifies that the company will no longer be listed on the stock exchange for “remove insurmountable pressure from us”.